16 results
8-K
EX-99.1
ONCR
Oncorus, Inc.
26 Jun 23
Hilco Streambank Seeks Offers to Acquire Patent Portfolio of Biopharmaceutical Company Oncorus
4:01pm
delivery system technologies, but also a starting place from which to accelerate costly R&D efforts.” Maersch continued, “Oncorus’ state-of-the-art
10-Q
2020 Q3
ONCR
Oncorus, Inc.
12 Nov 20
Quarterly report
8:01am
future tax payments may be limited or restricted.
We have generated significant NOL carryforwards and research and development tax credits, or R&D credits … and state R&D credit carryforwards of $2.3 million and $1.1 million, respectively. Our federal R&D credit carryforwards begin to expire in 2035 and our
10-K
2020 FY
ONCR
Oncorus, Inc.
10 Mar 21
Annual report
4:12pm
and research and development tax credits, or R&D credits, as a result of our incurrence of losses and our conduct of research activities since inception … . As of December 31, 2020, we also had federal and state R&D credit carryforwards of $3.3 million and $1.5 million, respectively. Our federal R&D credit
DRS/A
vr6mu5cwr5
29 Jul 20
Draft registration statement (amended)
12:00am
S-1
93qklu6noc2 fo2bgd
11 Sep 20
IPO registration
4:49pm
DRS/A
7jj fzui85
26 Aug 20
Draft registration statement (amended)
12:00am
424B4
93lqapiqs
2 Oct 20
Prospectus supplement with pricing info
12:00am
424B4
2au1j
12 Feb 21
Prospectus supplement with pricing info
4:23pm
DRS
ssszzfz
28 Jan 21
Draft registration statement
12:00am
DRS/A
bawo3kl6
20 Dec 19
Draft registration statement (amended)
12:00am
DRS
lse1dg634d
31 Oct 19
Draft registration statement
12:00am
DRS
EX-10.21
pv7 1a9px0jnnc93fa
28 Jan 21
Draft registration statement
12:00am
- Prev
- 1
- Next